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Hepatic iron overloadHepatic iron is known to regulate insulin signaling pathways and to inﬂuence insulin sensitivity in insulin re-
sistance (IR) patients. However, the role of insulin on hepatic iron homeostasis remains unexplored. Here, we
report that insulin promotes transferrin-bound iron uptake but shows no inﬂuence on non transferrin-bound
iron uptake in human hepatic HepG2 cells. As a mechanism we detected increased transferrin receptor-1
(TfR1) expression both at protein and mRNA levels. Unaltered stability of protein and transcript of TfR1
suggested the regulation at transcriptional level that was conﬁrmed by promoter activity. Involvement of
transcription factor hypoxia inducible factor-1 (HIF-1) was shown by mutational analyses of the TfR1 pro-
moter region and by electrophoretic mobility shift assay. When HepG2 cells were transfected with speciﬁc
siRNA targeted to 3′UTR of HIF-1α, the regulatory subunit of HIF-1; insulin-induced TfR1 expression and
iron uptake were inhibited. Transfection of cDNA expressing stable form of HIF-1α reversed the increased
TfR1 expression and iron uptake. These results suggest a novel role of insulin in hepatic iron uptake by a
HIF-1 dependent transcriptional regulation of TfR1.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Iron is one of the most essential micronutrients required for the
body to maintain energy homeostasis [1]. Due to its redox nature it
may participate in many enzymic electron transfer reactions. At the
same time, it may generate potentially dangerous hydroxyl radical
in the presence of reactive oxygen species (ROS) [2]. Thus, regulations
of iron homeostasis genes are highly coordinated mostly at the
post-transcriptional level [3]. Dysregulation of iron homeostasis
genes may lead to iron deﬁciency or overload conditions contributing
to several pathological conditions including iron overload related
hepatic cancer [4]. Conditions like alcohol consumption, excess use
of xenobiotics and hepatitis C infection contribute to hepatic iron
overload (HIO) [4]. Insulin resistance (IR) is also reported to be one
of the major contributors of HIO [4–7].
Insulin plays a critical role in energy metabolism and glucose
homeostasis [1,8]. After secretion from pancreatic beta cells into the
portal circulation, insulin primes the liver for rapid alterations in
hepatic carbohydrate and lipid metabolism [9]. Absence of insulin
in case of insulin-dependent diabetes mellitus (IDDM) or cellular
non-responsiveness to insulin in case of non-insulin-dependent
diabetes mellitus (NIDDM) leads to severe pathophysiological condi-
tions [9,10]. One of the body's responses in the early stage of insulin: +91 11 2674 1781.
opadhyay).
gy, The Lerner Research Insti-
rights reserved.resistance (IR) is to increase the synthesis and secretion of insulin
from pancreatic beta cells causing hyperinsulinemia [9–11]. IR and
coupled hyperinsulinemia lead to a variety of abnormalities, includ-
ing elevated triglycerides, low levels of HDL, enhanced secretion of
VLDL, increased vascular resistance, changes of peripheral blood
ﬂow and weight gain [12]. In some cases, a clinical-pathological syn-
drome of hepatic iron overload (HIO) in which disproportionately
raised serum and liver iron concentrations were reported [4–7]. Inter-
estingly, hepatic iron store was reported to regulate insulin signaling
pathways and to inﬂuence insulin sensitivity in IR patients suggesting
the existence of a cross talk between insulin and iron metabolism
[13,14]. Iron depletion by desferrioxamine (DFO) caused an increase
in insulin signaling in hepatoma cells as well as in rat liver [15]. Iron
depletion by phlebotomy also reported to improve insulin resistance
in patients with non-alcoholic fatty liver disease (NAFLD) and
hyperferritinemia [16,17]. Even insulin resistance related HIO was
improved by venesections and iron restricted diet [18,19] that
strengthened the concept of cross talk between insulin and iron me-
tabolism. Although these ﬁndings strongly suggest the role of iron
on insulin-induced cell metabolism the role of insulin on iron
metabolism is not clear so far [19].
Hepatocyte plays an important role for maintaining body iron
homeostasis and takes up both transferrin-bound iron (TBI) and
non transferrin-bound iron (NTBI) [20]. TfR1 binds iron saturated
transferrin (Tf) for cellular iron uptake in almost all cell types includ-
ing hepatocyte [21,22]; whereas, the mechanism of iron uptake from
NTBI is far less understood. Involvement of Zip 14 in iron uptake from
NTBI was reported recently [20,23]. Iron uptake from both TBI and
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[20]. Mutations in HFE affecting its function thus cause increased he-
patic iron uptake as detected in hereditary hemochromatosis [19,24].
However, several attempts to link HFE mutations responsible for
IR-associated hepatic iron overload have failed so far [4,7,19].
Inter-organ transport and uptake of nonheme iron is largely
performed by the Tf/TfR1 system [3,21,22]. During cellular iron deple-
tion, TfR1 is regulated mainly by post-transcriptional mRNA stability
mechanism mediated by increased binding of iron regulatory pro-
teins (IRP1/IRP2) to iron response elements (IRE) present in the
TfR1 3′UTR [3,21,22]. Iron depletion or hypoxia also regulates TfR1
by activating hypoxia inducible factor-1 (HIF-1) that binds to hypoxia
responsive element (HRE) present in the promoter of TfR1 [25,26].
HIF-1α, the regulatory subunit of HIF-1 is stabilized during oxygen
or iron depletion by a post-translational mechanism and transported
to the nucleus to bind the constitutional subunit HIF-1β to activate
HIF-1. HIF-1 then binds to HRE (5′-RCGTG-3′) of targeted genes. In
normal condition HIF-1α is highly unstable due to hydroxylation of
two proline residues (Pro402 and Pro564) by prolyl hydroxylases
(PHDs) that promotes ubiquitination and subsequent degradation
by proteasomal pathway [27–29]. Hypoxia leads to HIF-1α stabiliza-
tion due to inhibition of prolyl hydroxylses and subsequent decrease
in HIF-1α ubiquitination and degradation. Insulin induces several
genes including glucose transporters (Glut1 and Glut-3), several
glycolytic enzymes, erythropoietin and vascular endothelial growth
factor (VEGF) [30] by activating HIF-1 but its role on regulating TfR1
or iron homeostasis has not been reported so far. Insulin also induces
nuclear localization of Sp1 in the skeletal muscle cell [31]. Incidental-
ly, Sp1 binds to GC-rich region of TfR1 promoter and is responsible for
basal expression of TfR1 [32]. Considering all these, we hypothesize
that insulin has a direct role in hepatic iron uptake by regulating
TfR1 expression. In the present study, we revealed a novel role of
insulin in transferrin-bound iron uptake in human hepatic cells medi-
ated by HIF-1 induced transcription of TfR1.
2. Materials and methods
2.1. Materials
Human recombinant insulin was obtained from Invitrogen. Mono-
clonal antibodies to TfR1 and HIF-1α were obtained from Invitrogen
and Abcam respectively. Actin antibody was from Santa Cruz Biotech-
nology. All cell culture reagents and other reagents were obtained
from Sigma-Aldrich, if not mentioned otherwise.
2.2. Cell culture
Human hepatocarcinoma HepG2 cells (ATCC) were maintained in
Dulbecco's Modiﬁed Eagle's Medium (DMEM), supplemented with
10% heat-inactivated fetal bovine serum (Invitrogen), 100 units/ml
penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine in a hu-
midiﬁed atmosphere containing 5% CO2 at 37 °C (Forma-Scientiﬁc).
Human hepatocytes were obtained from Invitrogen (HMCS 10) and
cultured in Williams' Medium E as per Company's protocol. Cells at
50–60% conﬂuence were treated with appropriate concentrations of
insulin after serum deprivation as described earlier [33,34].
2.3. Western blot analysis
After the treatment as indicated in different experiments, cells
were lysed in buffer containing 50 mM HEPES, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 100 mM sodium ﬂuoride, 1 mM EGTA, 1 mM
EDTA, 2 mM sodium vanadate, 10 mM sodium pyrophosphate,
1 mM phenylmethylsulfonyl ﬂuoride and a protease inhibitor mix-
ture (Roche Applied Science). Then cell lysates were centrifuged at
13,000 ×g for 10 min; protein (40 μg) from the cleared supernatantwas resolved by either by 7.5% SDS- polyacrylamide gel electrophore-
sis (SDS-PAGE) and transferred to polyvinylidene diﬂuoride (PVDF)
membrane. PVDF membranes were subjected to immunoblotting
with antibody to TfR1 (1:1000) or actin (1: 1000). For immunoblot
analysis of HIF-1α, nuclear extracts (30 μg) were run into 7.5%
SDS-PAGE, transferred into PVDFmembranes and subjected to immu-
noblotting with monoclonal antibody to HIF-1α (1:1000). Following
incubation with horseradish peroxidase-conjugated secondary anti-
body, proteins were visualized by enhanced chemiluminescence
(ECL), according to the manufacturer's protocol (Amersham Biosci-
ences). To quantitate chemiluminescence signals ImageJ program
(http://rsbweb.nih.gov/ij/) was used as described detail in the
software.
2.4. Northern blot analysis
RNA was isolated from serum deprived HepG2 cells using TriPure
reagent (Roche Applied Science). Total RNA (20 μg) was denatured in
formamide/formaldehyde, electrophoresed through 1.2% agarose gel
containing 6% formaldehyde, and then blotted onto nylon mem-
branes (Schleicher & Schuell). After cross-linking by ultraviolet irradi-
ation, membranes were hybridized to a fragment of human TfR1
(generated by RT-PCR) or HIF-1α cDNA (Novus biologicals) and la-
beled by random priming with [α-32P]dCTP using a New England
Biolab Kit. Quantitation of the blots was performed by using ImageJ
program.
2.5. Reverse transcriptase polymerase chain reaction
Total RNA (4 μg) was used for each sample to perform
semi-quantitative RT-PCR by using one tube RT-PCR kit (Roche).
The following primers were used for hTfR1 gene: Forward: 5′ GCT
TGA AGA TCG TTA GTA TCT AAC 3′ and Reverse: 5′ CTA ACA CAG
TAA AGG TCA TGC AAG 3′; human β-actin: Forward, 5′ GAC ATG
GAG AAA ATC TGG CAC CAC 3′ and reverse, 5′ GAT GGA GTT GAA
GGT AGT TTC GTG 3′. TfR1 mRNA stability assay was performed as de-
scribed earlier [35,36]. For quantitative RT-PCR, TfR1 and control
β-actin mRNA transcripts were measured by a two-step RT-PCR
using the same set of primers with the Applied Biosystems 7500
real time PCR system. cDNA synthesis was performed with a reverse
transcription reagents kit (Applied Biosystems). Transcripts were am-
pliﬁed in duplicates with 100 pmol of speciﬁc sense and antisense
primers in a 50 μl reaction mixture containing 25 μl of 2× SYBR
Green PCR Master Mix (Applied Biosystems) that underwent 95 °C
activation for 10 min, followed by 40 repetitions of denaturation at
95 °C for15 s, annealing at 56 °C for 30 s, and 1 min extension at
60 °C. TfR1/β-actin ratios were calculated using 7500 system SDS
Software (Applied Biosystems).
2.6. Construction of FLAG-tagged TfR1 cDNA and veriﬁcation of TfR1
protein stability by insulin
The human TfR1 cDNA was subcloned from pCD-TfR1 (ATCC) to
NotI and BamHI sites of p3XFLAG-CMV-7.1 vector (Sigma). The
clone was veriﬁed by sequence analysis. The construct was
transfected in HepG2 cells along with pGL3-Control (to verify trans-
fection efﬁciency) and after insulin treatment Western blot analyses
were performed in the cell extract using TfR1, FLAG, luciferase and
actin antibodies.
2.7. Cloning of TfR1 promoter and construction of mutants
Human TfR1 promoter region (from−114 to +14 of transcription
start site) was ampliﬁed by PCR from genomic DNA and was cloned
between SacI and XhoI restriction sites in pGL3 basic vector
(Promega) behind the luciferase. Sequential deletion mutations
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site-directed mutagenesis. The following forward primers were used
for different deletion mutation products of TfR1 promoter: (−114
to +14) — 5′ ATA CAT GAG CTC GAT CTG TCA GAG 3′; (−95 to
+14) — 5′ ATA CAT GAG CTC CGA GCG TAC GTG 3′; (−82 to +14)
— 5′ ATA CAT GAG CTC CTC AGG AAG TGA 3′ (underline denotes
SacI). In all cases 5′ ATA TTG CTC GAG TAT CCC GAC GCT 3′ (underline
denotes XhoI) was used as reverse primer. Site directed mutation of
HRE was performed using megaprimer method [33,34] using 5′ CCT
GAG GCt ttt ACG CTC GCG 3′ as primer and −114 to +14 construct
as template. This fragment was further cloned into pGL3 basic vector
between SacI and XhoI restriction sites.2.8. Transient transfection of cells and reporter gene assays
To determine transcriptional efﬁciency of chimeric TfR1 promoter
constructs, HepG2 cells were transiently transfected for 6 h with a re-
porter plasmid (1.5 μg) using Lipofectamin 2000 (Invitrogen). To
monitor transfection efﬁciency, a reporter gene construct (0.25 μg)
containing β-galactosidase behind an SV40 promoter was co-
transfected as described earlier [34]. Transfected cells were allowed
to recover for 6 h in DMEM with 10% fetal bovine serum and after
serum deprivation were incubated with insulin for 16 h. Luciferase
(Promega) and β-galactosidase (Invitrogen) activities in cell extracts
were determined as described in the company's protocol.2.9. Preparation of nuclear extracts
Nuclear extract was prepared from HepG2 cells as described before
[34,37]. Brieﬂy, 1×108 cells were washed with ice-cold phosphate-
buffered saline and then with a solution containing 10 mM Tris–HCl,
pH 7.8, 1.5 mM MgCl2, and 10 mM KCl, supplemented with a
protease inhibitor mixture containing 0.5 mM dithiothreitol, 0.4 mM
phenylmethyl-sulfonyl ﬂuoride and 2 μg/ml each of leupeptin, pepstatin
and aprotinin. After incubation on ice for 10 min, cells were lysed by 10
strokes with a Dounce homogenizer and the nuclei were pelleted. The
pellet was resuspended in a solution containing 420 mM KCl, 20 mM
Tris–HCl, pH 7.8, 1.5 mM MgCl2 and 20% glycerol, supplemented with
protease inhibitor mixture described above and incubated at 4 °C with
gentle agitation. The nuclear extract was centrifuged at 10,000×g for
10 min, and the supernatant was dialyzed twice against a solution of
20 mM Tris–HCl, pH 7.8, 100 mM KCl, 0.2 mM EDTA, and 20% glycerol.
Protein concentration was determined using Bio-Rad reagent with
bovine serum albumin as standard.2.10. Electrophoretic mobility shift analysis (EMSA)
Sequences of sense strands for oligonucleotide probes used for
EMSA were as follows: 5′ AGC GTA CGT GCC TCA GGA AGT GAC 3′
(W — wild HRE) and 5′-AGC GTA AAA GCC TCA GGA AGT GAC 3′
(M — mutant HRE). The sense and antisense strands were annealed,
gel-puriﬁed, and end-labeled with [γ32P]ATP using T4-polynucleotide
kinase (Promega). Unincorporated nucleotide was removed by gel
ﬁltration using G-25 Sephadex columns (Quick SpinTM TE, Roche
Applied Science). To measure DNA-protein interaction, 1×105 cpm of
oligonucleotide probe was incubated with 5 μg of nuclear extract and
0.5 μg of sonicated, denatured salmon sperm DNA (Invitrogen) in
10 mM Tris–HCl, pH 7.8, 50 mM NaCl, 1 mM MgCl2, 1 mM EDTA,
5 mM dithiothreitol and 5% glycerol for 20 min at 4 °C in a total vol-
ume of 20 μl. The reaction mixture was subjected to electrophoresis
(200 V in 0.3× Tris-buffered EDTA solution at 4 °C) using 5%
nondenaturing polyacrylamide gel. Dried gels were subjected to auto-
radiography up to 24 h.2.11. Knocking down of HIF-1α by siRNA
Custom made siRNA for HIF-1α, control siRNA and transfection re-
agents were purchased (Sigma). HepG2 cells were transfected with the
HIF-1α siRNA targeted to its 3′UTR. Target sequence 5′ AAT GCC AGA
TCA CAG CAC ATT 3′ (from 3167 to 3187 nucleotide of human HIF-1α
mRNA) was designed by siRNA target ﬁnder site of Ambion (http://
www.ambion.com/techlib/misc/siRNA_ﬁnder.html). HIF-1α siRNA
(80 μg) was transfected in 12-well plates using N-TER™ nanoparticle
siRNA Transfection System (Sigma). In some cases, after 24 h of transfec-
tion and recovery, cells were retransfected with pcDNA3-HIF-1α (P/A)
or only pcDNA3 (4 μg/well) using Oligofectamine (Invitrogen). HIF-1α
cDNA (P/A) (corresponding only to its open reading frame)wasmutated
at 402 and 564 from proline to alanine (kind gift from Dr. Ritu
Kulshreshtha, Indian Institute of Technology, New Delhi, India) to avoid
proline hydroxylation and subsequent ubiquitination and proteasomal
degradation. After transfection serum deprived cells were treated with
insulin and Western blot analyses were performed for HIF-1α, TfR1
and actin.2.12. Iron uptake
2.12.1. 55Fe loading to Apotransferrin
55FeCl3 (NEN) and nitrilotriacetate (NTA) were mixed in 1:50
molar ratio in 300 μl of carbonate buffer (10 mM NaHCO3, 250 mM
Tris–Cl pH 7.4). After mixing thoroughly it was kept at room temper-
ature for 10–15 min. Apo-transferrin (1.5 μg dissolved in 100 μl
carbonate buffer) was incubated with 55Fe-NTA in 1:2 ratios at
room temperature for 1 h and then kept at 4 °C for overnight [38].
The complex was passed through G-50 sephadex column to purify
the 55Fe-Tf complex from the unbound 55Fe-NTA.2.12.2. 55Fe-Tf uptake assay
Cells were grown in 12 well plates. Sub-conﬂuent cells were treat-
ed with insulin or desferrioxamine (DFO, 150 μM) after serum depri-
vation. After requisite time, cells were incubated with 55Fe-Tf for
30 min at room temperature (25 °C) in serum free media. Then
cells were washed twice with wash-buffer (150 mM NaCl and
100 μM EDTA) to remove the externally bound 55Fe-Tf complex.
Cells were lysed with 200 μl of lysis buffer (0.1% NaOH and 0.1% Tri-
ton X-100) at 4 °C for 30 min [35] and lysate was used for counting
radioactivity by Liquid Scintillation Counter. Iron uptake was deter-
mined as pmol/106 cell/30 min.2.12.3. Non transferrin-bound iron (NTBI) uptake assay
A solution of 55Fe-NTA was prepared by mixing 55FeCl3 (NEN)
with a 5-fold molar excess of disodium salt of NTA [39]. To measure
iron uptake, 5×106 cells were incubated with 55FevNTA (1 μM) in
serum free medium for 30 min at 25 °C. Cells were washed twice
with 150 mM NaCl containing 10 μM EDTA (to remove surface-
bound iron) and cell-associated radioactivity was measured in cell
lysates (as described before) by Liquid Scintillation Counter. Iron
uptake was determined as pmol/106 cell/30 min.2.13. Statistical analysis
All experiments have been performed at least three times with
similar results and representative experiments are shown. Densito-
metric results are normalized with respect to internal controls and
are expressed relative to the results in untreated control. Error bars
represent standard deviations with a p value b0.06 was taken to be
statistically signiﬁcant.
296 S. Biswas et al. / Biochimica et Biophysica Acta 1832 (2013) 293–3013. Results
3.1. Insulin regulates transferrin-mediated iron uptake in human hepatic
cells by promoting TfR1 expression
To determine the ability of insulin to promote iron uptake, HepG2
cells were treated with insulin (0–30 nM) and transferrin-bound iron
(55Fe-Tf) uptake was examined. A dose dependent increase in 55Fe-Tf
uptake up to about 1.8-fold was detected by insulin (0–30 nM) treat-
ment (Fig. 1A). Any further increase in iron uptake was not found
with further increase in insulin concentration (data not shown).
Treatment with iron chelator DFO (150 μM) increased intracellular
55Fe by about 2.4-fold (Fig. 1A). Insulin had no effect on non
transferrin-bound iron (NTBI) uptake as no increase in intracellular
55Fe was detected in insulin (30 nM) treated HepG2 cells after incu-
bation with 55Fe-NTA (Fig. 1B). To ﬁnd any appreciable iron uptake
from 55Fe-Tf, more than 8 h of insulin treatment was required and
maximum was detected after 16 h of insulin treatment (Fig. 1C).
To ﬁnd out whether insulin-induced increase in 55Fe uptake was
due to increase in TfR1 expression, we treated HepG2 cells with in-
creasing concentration of insulin and steady state TfR1 level wasFig. 1. Role of insulin on iron uptake in HepG2 cells. A. Serum deprived cells were treat-
ed with insulin (0–30 nM) or DFO (150 μM) for 16 h then incubated with 55Fe-Tf. After
30 min intracellular radiolabled iron was determined as described in Materials and
methods. Results were representative of three independent experiments performed
in triplicate, pb0.04. B. Serum deprived HepG2 cells were treated with insulin
(30 nM) for 16 h and then incubated with 55Fe-NTA. Intracellular radiolabeled iron
was determined after 30 min. Results were representative of three independent exper-
iments performed in triplicate, pb0.02. C. Similarly, cells were treated with insulin
(30 nM) for different period of time or remained untreated. After each time period
cells were incubated with 55Fe-Tf. After 30 min intracellular radiolabled iron was
detected. Results were determined from three independent experiments performed
in triplicate, pb0.04.determined in cell lysate by Western blot analysis. A concentration
dependent increase in TfR1 level was detected by insulin treatment
(Fig. 2A). The maximal increase (about 2-fold) was detected by 10
to 30 nM of insulin treatment. The iron chelator DFO (100 μM) was
used as a positive control (Fig. 2A). After insulin treatment more
than 8 h was required to detect any appreciable change in TfR1
level and maximum increase was found at 16 h (Fig. 2B). To further
conﬁrm the role of insulin on TfR1 expression, human primary hepa-
tocytes were treated with insulin (30 nM) or DFO (150 μM) for 16 h
and Western blot analysis was performed in cell lysates. TfR1 expres-
sion was increased about 2.1-fold by insulin and about 2.6-fold by
DFO treatment (Fig. 2C). Since, insulin was reported to inhibit prote-
olysis [40], we examined whether insulin had any inﬂuence on TfR1
stability at the protein level. To verify that cells were treated with in-
sulin or remain untreated for 14 h and then protein synthesis inhibi-
tor cycloheximide (CHX, 10 μg/ml) was added. TfR1 expression was
determined by Western blot analysis in cell lysates prepared after 0,
3, 6 and 9 h of CHX addition. Reduction of 50% TfR1 expression was
detected at about 6 h in both insulin treated and untreated cells
(Fig. 2D) suggesting insulin had no role in TfR1 protein stability. As
a second approach, cells were transfected with plasmid encoding
FLAG-tagged TfR1 and pGL3-control (as transfection control) and
then treated with insulin or none. After 14 h, cell lysates were pre-
pared and analyzed by Western blotting. The data showed while en-
dogenous TfR1 was increased (70%) but epitope-tagged TfR1
(detected by FLAG antibody) remained unchanged (Fig. 2E) further
suggesting no role of insulin on TfR1 stabilization at protein level.
3.2. Insulin regulates TfR1 synthesis by a transcriptional mechanism
To further determine the mechanism Northern blot analysis was
performed and about 2-fold increase in TfR1 mRNA was detected
after 16 h of insulin treatment (Fig. 3A). A similar result of about
2.1-fold increase of TfR1 transcript was detected in insulin treated
cells by qPCR analysis. Since, TfR1 is mainly regulated by
post-transcriptional mRNA stability mechanism by iron depletion
[3,21,22]; we determined half-life of TfR1 transcript in insulin treated
and untreated cells. Insulin treatment did not alter TfR1 mRNA
half-life (about 2 h) as reported earlier [35,36] (Fig. 3B–C) indicating
the regulation was primarily at the transcription level. To test that
promoter region (−114 to +14 from transcription start site) of
TfR1 was cloned into pGL3-basic vector behind luciferase gene and
transfected into HepG2 cells along with β-galactosidase (coupled
with SV40 promoter). After 16 h of insulin treatment luciferase and
galactosidase activities were determined in cell extracts. The result
showed about 2.1-fold increase in promoter activity (Fig. 4A)
conﬁrming TfR1 regulation by insulin was due to transcriptional
mechanism. To identify the responsible element(s) conferring
insulin-mediated increase in TfR1 expression we sequentially deleted
the promoter region from the proximal end (−95 and−82) and ex-
amined the promoter activity. Insulin induced TfR1 promoter activity
in−95 construct transfected cells remained unaffected, but the activ-
ity was abolished in−82 construct transfected cells (Fig. 4A). This re-
sult suggested that the −95 to −82 bp region of the TfR1 promoter
was critical for the transcriptional regulation by insulin. To ﬁnd the
presence of any known responsive element within this region, we
searched transcription factor binding consensus sequence between
−95 and −82 region upstream of the transcription start site and a
hypoxia responsive element (HRE, TACGTGCC) was detected within
that region (Fig. 4A). To examine the involvement of HRE in
insulin-induced activation of TfR1 promoter, the HRE was mutated
from 5′ TACGTGCC 3′ to 5′ TAAAAGCC 3′ in the −114 construct and
the mutated construct (Mut-HRE) was transfected. In response to in-
sulin (30 nM) no appreciable change in luciferase activity was
detected in Mut-HRE transfected cells, while wild-HRE transfected
cells showed more than two-fold increase in luciferase activity
Fig. 2. Role of insulin on transferrin receptor-1 expression. A. Cells were treated with insulin (0–30 nM) or desferrioxamine (100 μM) for 16 h; TfR1 (upper panel) and actin (mid-
dle panel) expressions were detected in cell lysates by Western blot analyses. Relative expression was determined by densitometric analysis from three independent experiments
(bottom panel), pb0.02 B. Similarly, cells were treated with insulin (30 nM) or remained untreated. TfR1 (upper panel) and actin (middle panel) expressions were determined by
Western blot analysis from cell lysates isolated after 8 h, 16 h or 24 h of insulin treatment. Relative expression was determined by densitometric analysis from three independent
experiments (bottom panel), pb0.03. C. Similarly, human primary hepatocytes were treated with either insulin (30 nM) or desferrioxamine (150 μM) or remain untreated for 16 h
and Western blot analysis was performed with cell lysates for TfR1 (upper panel) and actin (bottom panel). Result represents one of the three independent experiments of similar
results. D. Cycloheximide (CHX, 10 μg/ml) was added after 14 h of insulin treated or untreated cells and cell lysates were obtained after 0, 3, 6 and 9 h of CHX treatment. Western
blot analyses were performed using TfR1 and actin antibodies in cell lysates. Relative level of TfR1 after comparing with actin (in %) was obtained from three independent exper-
iments, pb0.05. Decrease of 50% TfR1 level in compare to 0 h of CHX addition has been shown by arrow. E. Cells were transfected with FLAG-tagged TfR1 and pGL3-control vector or
kept untransfected (UT). Then transfected cells were treated with insulin (none or 30 nM) for 14 h. Western blot analyses were performed with cell lysates with antibodies of TfR1,
FLAG, luciferase and actin. Results shown are representative of one of the three independent experiments with similar results.
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tion of TfR1 in HepG2 cells.
3.3. Identiﬁcation of HIF-1 as the transcription factor responsible for
insulin-induced TfR1 regulation
When 32P labeled double stranded TfR1-HRE probe was incubated
with nuclear extract isolated from insulin treated HepG2 cells, an
insulin-induced DNA binding activity was detected by EMSA
(Fig. 5A). To ﬁnd out speciﬁcity of the binding, cold competition
assay was performed. When 10× or 30× molar excess of the cold
probe was added with nuclear extract from insulin treated HepG2
cell, the insulin-induced binding (shown by the solid arrowhead) aswell as non-speciﬁc (NS) binding was competed out. But when 10×
or 30× molar excess of unlabeled mutant-HRE was added only the
non speciﬁc binding was competed out but insulin-induced DNA
binding remained unaltered conﬁrming the binding was due to HRE
(Fig. 5A). To conﬁrm that insulin-induced HRE binding was actually
due to HIF-1, supershift analysis was performed using HIF-1α and
HIF-1β antibody. When nuclear extract from insulin-induced HepG2
cell was incubated with either HIF-1α or HIF-1β antibody or both to-
gether; in all cases the speciﬁc insulin-induced DNA binding activity
was either shifted to higher mobility or not entered into the gel prob-
ably due to a larger complex formation (Fig. 5B). This experiment
strongly suggested that insulin-induced increase in TfR1 synthesis
was due to HIF-1 binding to HRE present in the TfR1 promoter.
Fig. 3. Insulin promotes TfR1 mRNA expression. A. Total RNA was isolated after 16 h of
insulin (30 nM) treatment and abundance of TfR1 mRNA was determined after hybrid-
izing with 32P labeled human TfR1 cDNA (left upper panel). The abundance of loaded
RNA was determined by β-actin hybridization (left bottom panel). Relative expression
was determined by densitometric analysis (right panel), pb0.03. B. To determine the
mRNA stability of TfR1, actinomycin D (7.5 μg/ml) was added to insulin (30 nM) treat-
ed and untreated cells after 12 h of treatment. Total RNA was isolated at 0, 1.5, 3.0 and
4.5 h of actinomycin D addition and reverse-transcriptase PCR was performed with
speciﬁc primers of human TfR1 and β-actin. C. Relative expression of TfR1 mRNA was
represented (in %) from three independent experiments, pb0.05. Decrease of 50%
TfR1 mRNA level in compare to 0 h of actinomycin D addition has been shown by
arrow.
Fig. 4. Insulin induces TfR1 promoter activity. A. Chimeric pGL3-basic vectors
containing different regions of human TfR1 promoter were transfected in HepG2
cells (with a plasmid containing β-galactosidase to correct for transfection efﬁciency)
and then treated with insulin (30 nM) after serum deprivation. After 16 h, luciferase
activity in cell extracts was measured by chemiluminescence and normalized for
β-galactosidase activity. Data represents means±S.D., n=3, pb0.06. B. Chimeric
pGL3 basic vector containing HRE (−114 to +14 segment of TfR1 promoter) either
wild (Wild) or mutated (Mut) was transfected along with β-galactosidase plasmid.
After recovery cells were serum deprived and treated with insulin (16 h, 30 nM).
Luciferase activity in cell extracts was measured and normalized for β-galactosidase
activity. Data shown are the means±S.D., n=3, pb0.04.
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To conﬁrm the role of HIF-1 in insulin-induced TfR1-mediated iron
uptake, HepG2 cells were transfected with HIF-1α siRNA targeted to
its 3′UTR and also with a control siRNA. Western blot analysis showed
about 2- fold increase in HIF-1α protein level after 16 h of insulin
treatment in control siRNA transfected cells (Fig. 6A). Interestingly,
we detected cross reactive protein bands with similar mobility with
the HIF-1α antibody in HepG2 cells that was not affected by HIF-1α
siRNA. The same antibody did not show any cross reactivity in other
cell types in normoxic condition (data not shown). Insulin-induced
HIF-1α expression was inhibited more than 90% by HIF-1α siRNA
transfected cells (Fig. 6A). To show the speciﬁcity of siRNA,
HIF-1α-siRNA (targeted to its 3′UTR) transfected cells were further
transfected with pcDNA3-HIF-1α (P/A) containing mutations at
402-proline and 564-proline to alanine to overcome the effect of
prolyl hydroxylase mediated HIF-1α protein degradation. Resultshowed HIF-1α expression was restored in pcDNA3-HIF-1α (P/A)
transfected cells but not in pcDNA3 transfected cells (Fig. 6B). When
HIF-1α siRNA transfected cells were treated with insulin, TfR1 ex-
pression was inhibited by about 90% in compared to cells transfected
with control siRNA (Fig. 6C). Interestingly, basal TfR1 level was not af-
fected by HIF-1α-siRNA indicating HIF-1α was responsible only for
insulin-induced TfR1 synthesis (Fig. 6C). When transferrin-bound
iron uptake capacity of HIF-1α siRNA transfected cells was tested by
incubating with 55Fe-Tf, more than 80% of insulin-induced iron up-
take was blocked in compared to control siRNA transfected cells
(Fig. 6D). A similar result was also obtained with another set of
siRNA targeted to HIF-1α coding region (target sequence: 5′ AAC
ACA CAG CGG AGC TTT TTT 3′) (S1). All these results strongly suggest
insulin regulates TfR1 expression in HepG2 cells by a HIF-1 depen-
dent mechanism to stimulate iron uptake.
4. Discussion
Glucose metabolism is critically dependent on cellular iron avail-
ability [1,13] and insulin [8–12]. Hepatic iron store also inﬂuences in-
sulin sensitivity and signaling [13–18]; however, any direct role of
insulin on hepatic iron homeostasis has not been explored. In this
study we demonstrated a novel role of insulin in promoting iron
Fig. 5. Identiﬁcation of HIF-1 as transcription factor mediating insulin-induced TfR1
promoter activity. A. EMSA was performed with nuclear extract isolated from insulin
(30 nM, 12 h) treated and untreated cells. Induction of insulin-induced DNA-protein
complex was shown with arrow (closed). NS denotes non-speciﬁc binding. Competi-
tion experiment was carried out with 10- or 30- fold molar excess unlabeled probes
containing either wild HRE (W) or mutant-HRE (M). Unlabeled probes were added
1-minute prior the addition of radiolabled probe. B. Insulin treated nuclear extract
was incubated with either HIF-1α and/or HIF-1β antibody for 1 h prior to EMSA. ‘SS’
denotes super-shifted HIF-1 complex. Results are representative of one of the three
independent experiments.
Fig. 6. HIF-1α siRNA blocks insulin-mediated TfR1 expression and iron uptake. A. Cells
were transfected with either control (si cont) or HIF-1α speciﬁc siRNA (si HIF-1α) and
then treated with insulin (30 nM) for 16 h. HIF-1α and actin expressions were deter-
mined in nuclear extracts by Western blot analyses. B. After 24 h of transfection with
HIF-1α speciﬁc siRNA, cells were retransfected with either pcDNA3 (vector control)
or pcDNA3-HIF-1α (P/A) for 24 h as described details in Materials and methods.
Then cells were treated with insulin (30 nM) or remain untreated for 16 h and West-
ern blot analyses were performed in nuclear extracts with HIF-1α and actin antibodies.
C. In control (si cont) or HIF-1α speciﬁc siRNA (si HIF-1α) transfected cell lysates (as
described in ‘A’) TfR1 and actin expressions were determined. D. Similarly, control
and HIF-1α siRNA transfected cells were treated with insulin for 16 h and 55Fe-Tf
uptake was determined as described earlier. Results were from three independent
experiments performed in triplicate, pb0.04.
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similar regulation of TfR1 was also detected in insulin treated
human primary hepatocytes. We further revealed that insulin-
induced TfR1 synthesis was mediated by transcription factor HIF-1
by binding to the single HRE present in the TfR1 promoter. Our result
established a direct and novel link between iron and energy metabo-
lism in liver cell in response to insulin.
We detected about 1.8-fold increase in radiolabeled transferrin-
bound iron uptake after 16 h of insulin treatment (Fig. 1) that was
consistent with increase in TfR1 expression by insulin (Fig. 2B) indi-
cating TfR1 synthesis was the key cellular event for insulin-induced
iron uptake. This was further conﬁrmed by blocking insulin-induced
TfR1 expression using HIF-1α siRNA, and 55Fe-transferrin uptake
(Fig. 6C–D; S1). All these results strongly suggest that insulin pro-
motes iron uptake in hepatic cell by HIF-1 dependent synthesis of
TfR1. Earlier, we reported the ability of insulin in ceruloplasmin(Cp) synthesis in HepG2 cells by HIF-1 dependent mechanism [33].
Given the role of Cp in loading iron into transferrin; the binding com-
ponent of TfR1, a global role of insulin-mediated HIF-1 activation in
promoting hepatic iron uptake could be assumed.
The regulation of TfR1 due to stability of its mRNA has been studied
overwhelmly [3,21,41]. Our result indicated that insulin apparently had
no effect on TfR1 mRNA stability as measured by semi-quantitative
RT-PCR (Fig. 3B–C). Even though the method we used was
semi-quantitative in nature, the half-life of TfR1 was detected at
about 2 h that closely matched with the earlier results [35,36]. But
given the earlier report of increased IRP1 expression at mRNA level in
differentiated adipocytes resulting into increased IRP–IRE interaction
[42] we are not completely ruling out the possibility of post-
transcriptional regulation of TfR1 mRNA in insulin-induced hepatic
cells. Of note, that insulin was used as one of the components along
with isobutylmethylxanthine and dexmathosone for differentiation of
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insulin in HepG2 cells.
Interestingly, regulation of TfR1 at the transcription level is less
reported. The presence of an active HRE in TfR1 promoter and its in-
volvement in TfR1 regulation by iron depletion or hypoxic exposure
was reported in hepatic cells [25,26]. Basal synthesis of TfR1 is depen-
dent on GC-rich Sp1 binding site [32]. A rapid insulin-induced nuclear
localization of Sp1 was detected in skeletal muscle cells [31]; where-
as, role of Ets-1 in TfR1 regulation was reported in erythroid cells
[43,44]. Among these transcription factors reported to control TfR1
expression in various cell types we could only detect the involvement
of HIF-1 in insulin-induced TfR1 synthesis in HepG2 cells. Although,
the ability of insulin in HIF-1 activation in muscle and hepatic cell
was reported earlier [30,33,34], but the actual mechanism of activa-
tion had not been elucidated so far. Post-translational protein stability
mechanism of regulatory subunit HIF-1α during hypoxia, exposures
to other hypoxia mimetic like cobalt or iron depletion is the paradigm
of HIF-1 activation. In normal condition, hydroxylation of two proline
residues of HIF-1α (Pro402 and Pro564) promotes ubiquitination and
subsequent proteasomal degradation [27–29]. Three different HIF
prolyl-hydroxylases termed PHD1, PHD2, and PHD3 are able to hy-
droxylate these HIF-1α proline residues. PHDs hydroxylate HIF-1α
using oxygen and 2-oxoglutarate as substrates and iron and ascorbate
as cofactors [45]. Since cellular iron level reciprocally regulates
PHD activity affecting HIF-1α stabilization; thus, insulin-induced
iron-uptake should inhibit HIF-1 activation by increasing PHD activi-
ty. As a result there should be a decrease in TfR1 expression in case of
HIF-1 activation by insulin which depends on PHD activity exclusive-
ly. We detected TfR1 expression even after 24 h of insulin treatment
(Fig. 2B) indicating involvement of a different or additional mecha-
nism other than PHD activity for insulin-induced HIF-1 activation. A
recent report demonstrated that insulin can increase HIF-1α mRNA
and protein level in 3T3-L1 adipocyte [46]. When we examined
HIF-1α mRNA level in insulin treated HepG2 cell, about 2-fold in-
crease in HIF-1α mRNA was detected by Northern blot analysis (S2)
suggesting that insulin-induced increase in HIF-1α mRNA level
could be one of the mechanisms of HIF-1 activation by insulin. The
degree of involvement of cellular PHD activity and increased HIF-1α
transcript in insulin-induced HIF-1 activation is not clear so far. It
needs further study to unravel the detailed mechanism of HIF-1 acti-
vation by insulin.
Earlier studies reported the ability of insulin in increased TfR1
recycling [47,48] in adipocyte. But the role of insulin in TfR1 synthesis
has not been reported so far in any other cells including adipocyte.
We detected insulin-induced TfR1 synthesis and 55Fe-transferrin up-
take only after 8 h of treatment indicating TfR1 recycling may not
have any signiﬁcant role in insulin-induced 55Fe-transferrin uptake
in HepG2 cell. The previous study in adipocyte and the current
study in HepG2 cell though suggest a general role of insulin in cellular
iron uptake in sensitive cells. But the exact physiological importance
of insulin-mediated iron uptake is not clear so far. Insulin as a growth
factor may need the appropriate amount of micronutrient like iron for
its critical anabolic activity and energy generation from glucose.
Interestingly, redistribution and localization of TfR1 and glucose
transporters along with IGF-II receptor in to the surface from intracel-
lular compartment in insulin treated 3T3-L1 adipocytes [49] further
support that insulin-induced iron uptake in sensitive cells may be
important for energy generation.
The role of HIF-1 in iron homeostasis is well established during
hypoxia and iron deﬁciency [50]. But its role in cellular iron uptake
in normoxic condition has not been envisaged and shown before.
Our result also indicates an important role of HIF-1 in iron physiology
even in other conditions than hypoxia or iron deﬁciency. Taken to-
gether, we hypothesize that activation of HIF-1 and subsequent regu-
lation of iron homeostasis by insulin may help in the redistribution of
iron within and outside the tissues for cellular growth.The insulin-induced HIF-1 activation and resulting TfR1-mediated
iron uptake may be important for cellular growth but in a condition
like IR or hyperinsulinemia, this may contribute to the pathophysiol-
ogy of insulin resistance related HIO. When peripheral tissues like the
muscle and adipocyte become resistant to insulin [9,11], then the
body tries to compensate the ineffectiveness by increasing synthesis
and secretion of more insulin [9,11]. Thus, physiological concentra-
tion of insulin becomes higher than normal (hyperinsulinemia). In
the early stage of hyperinsulinemia hepatocyte remains sensitive to
insulin [9,11,51]. In this condition, higher insulin concentration may
increase hepatic iron uptake by increasing TfR1 expression resulting
into higher hepatic iron level as reported in IR-HIO patients [19,52].
Intracellular increase in iron level regulates iron-storage protein ferri-
tin synthesis [3,21,41]. Thus, insulin-induced TfR1mediated increase
in cellular iron level may result into increased ferritin level as
reported in IR-HIO patient [19,52]. However, cellular iron load also
depends on the expression of ubiquitous iron release component
ferroportin, which contains an active IRE in its 5′UTR [3,21,41].
Thus, increase in iron pool in hepatocyte should increase ferroportin
expression by decreasing IRP interaction with IRE present in its 5′
UTR. However, hepcidin degrades ferroportin by a posttranslational
mechanism [3,21,41]. About 50% increase in serum prohepcidin
level was reported in type 2 diabetes patients than normal glucose
tolerant subjects [53]. Higher cellular iron load or hyperferritinemia
was reported with higher hepcidin level in serum [19,53]. Increased
hepcidin level should decrease ferroportin expression to restrict
iron within cell. All these events may be initiated with chronic in-
crease in hepatic iron load from increased TfR1 expression by insulin.
Although, our study in HepG2 cell culture may be extrapolated to this
model of hepatic iron overload; but it is not possible to examine all
these chronic events leading to pathological condition like IR-HIO in
cell culture study. To overcome this limitation it needs a combination
of in vivo and in vitro studies for better understanding of the molec-
ular mechanism of IR-HIO in the future.
In summary, we identiﬁed a novel function of insulin in TfR1 me-
diated iron uptake in hepatic cell mediated by HIF-1. The importance
of which in physiology is not clear so far but this may be one of the
contributors of hepatic iron overload condition in hyperinsulinemia
or IR.




FAC Ferric ammonium citrate
Ft-H Ferritin-H
HIO Hepatic iron overload
HRE Hypoxia responsive element
HIF-1 Hypoxia inducible factor-1
IDDM Insulin-dependent diabetes mellitus
IR Insulin resistance
IRP Iron regulatory protein
IRE Iron responsive element
LIP Labile iron pool
NAFLD Non-alcoholic fatty liver disease
NIDDM Non-insulin-dependent diabetes mellitus
NTA Nitrilotriacetate
NTBI Non transferrin-bound iron
ROS Reactive oxygen species
RT-PCR Reverse transcriptase polymerase chain reaction





VEGF Vascular endothelial growth factor
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